ARTICLE | Clinical News

CVac: Phase II/III started

February 13, 2012 8:00 AM UTC

Prima BioMed began the double-blind, placebo-controlled, international Phase II/III CANVAS trial to evaluate intradermal CVac over 44 weeks in about 800 women who are in complete remission after completing first-line treatment of surgery followed by chemotherapy. Patients will receive CVac every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses. The product has Orphan Drug designation in the U.S. and EU. ...